UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
PHARMACEUTICAL COMPANIES

Exeltis

Pharmaceutical company specialising in women's health and dermatology

Exeltis logo

Exeltis

Pharmaceutical company specialising in women's health and dermatology

Visit Website

About Exeltis

Founded as part of the Insud Pharma group, Exeltis has built its reputation on specialised therapeutics in women's health, respiratory medicine, and dermatology, operating across more than 50 countries with a portfolio oriented toward prescription medicines and consumer healthcare products.

The company occupies a distinct position in the mid-size global pharma landscape, combining a strong research and development pipeline with in-licensing partnerships that allow it to bring differentiated therapies to market in geographies where large multinationals often have limited commercial focus. Its women's health division is particularly recognised, covering contraception, gynaecological conditions, and reproductive medicine, with branded products established across Europe, Latin America, and beyond.

Exeltis operates commercial affiliates and distribution partnerships across Europe, North and South America, Asia-Pacific, and the Middle East, supporting both branded prescription products and over-the-counter lines. The group's manufacturing and regulatory capabilities are anchored through the wider Insud Pharma ecosystem, which includes production facilities across multiple continents and a track record in generic and specialty pharmaceuticals.

In respiratory medicine, Exeltis markets inhaled therapies and supports patient-focused programmes aligned with international treatment guidelines. Its dermatology portfolio addresses both prescription and consumer-facing skin conditions, reflecting the company's broader strategy of combining specialty prescription medicines with accessible healthcare products under one commercial umbrella.

Further information is available at exeltis.com.

Areas of Expertise

Consumer HealthcareDermatologyReproductive MedicineRespiratory MedicineSpecialty PharmaceuticalsWomen's Health

Services & Capabilities

Consumer HealthcareDermatologyReproductive MedicineRespiratory MedicineSpecialty PharmaceuticalsWomen's Health
Similar Companies

More in Pharmaceutical Companies

A

Alfasigma USA

Formed to bring the portfolio of its Italian parent directly to North American prescribers, Alfasigma USA is the dedicated US commercial subsidiary of Alfasigma S.p.A., the Bologna-headquartered pharmaceutical group created in 2016 through the merger of Alfa Wassermann and Sigma-Tau. The parent operates in more than 90 countries and employs over 3,000 people globally, with a broad product portfolio spanning gastroenterology, hepatology, metabolism and rare disease. US Commercial and Medical Affairs Operations Alfasigma USA manages the full commercial lifecycle for its prescription medicines in the United States, covering regulatory submissions to the FDA, medical affairs, pharmacovigilance and market access. The subsidiary works directly with physicians, gastroenterologists, specialist prescribers, pharmacists and payer organisations to support appropriate product access and patient support programmes. The gastroenterology and hepatology franchise is a core focus of the US operation, reflecting the parent group's longstanding research heritage in digestive health and liver function. Alfasigma USA operates within the frameworks established by the FDA and applicable federal healthcare regulations, functioning as an accountable commercial and regulatory presence rather than relying on third-party licensing or distribution arrangements. Further information is available at alfasigmausa.com.

View profile
A

ACIC

Rooted in the North American pharmaceutical market since 1968, ACIC has built its reputation on guiding active pharmaceutical ingredients from early sourcing through to commercial production. The company was established by Luciano Calenti, who arrived in Canada to help create one of the country's first synthetic antibiotic manufacturing facilities, with an initial focus on antibiotics such as amoxicillin. ACIC subsequently developed exclusive partnerships with European manufacturers to supply and distribute APIs, ensuring adherence to both FDA and Health Canada regulatory requirements from the outset. Over the decades, the company expanded its technical capabilities significantly. ACIC opened its first R&D laboratory dedicated to chemical synthesis and later constructed a synthesis plant in Brantford, Canada, supporting both research and commercial-scale production. That facility received approval from the US FDA and Health Canada's Therapeutic Products Directorate, reflecting the dual-market compliance that has characterised ACIC's approach throughout its history. The company's work has spanned APIs, injectables, and the development of joint venture manufacturing facilities across North America. Today ACIC positions itself as an integrator of pharmaceutical equipment solutions alongside its pharmaceutical services, operating under the guiding principle of taking products from molecule to market through innovation. This combination of long-standing regulatory experience, synthesis infrastructure, and strategic manufacturer partnerships places ACIC within the broader contract and specialist services segment of the North American pharmaceutical industry. Further information is available at acic.com.

View profile
A

Astex Pharmaceuticals

Astex Pharmaceuticals applies its proprietary Pyramid Discovery Platform to the identification and development of drug candidates in oncology and central nervous system (CNS) disorders. Operating at the intersection of cutting-edge technology and translational science, the company has assembled research and development teams focused on generating innovative solutions to the complex challenges that characterise both cancer biology and CNS disease. The company has built a broad product portfolio spanning preclinical and clinical stages. Collaboration and licensing agreements with major pharmaceutical companies underpin part of that portfolio, and three partnered products have reached regulatory approval and are now available on the market. This track record of advancing candidates from discovery through to approved medicines reflects the depth of the company's drug discovery capabilities. Oncology and CNS Research Focus Astex's pipeline addresses two of the most challenging and resource-intensive areas of modern medicine. The oncology and CNS drug discovery programmes draw on proprietary technology to identify novel targets and chemical matter, with candidates progressing through preclinical characterisation into clinical evaluation. The organisation also supports early-career scientists through a postdoctoral research programme, reinforcing its commitment to sustaining innovation over the long term. Headquartered in the United Kingdom, Astex operates as a dedicated pharmaceutical research company with a clinical pipeline that continues to expand alongside its partnered development activities. Strategic partnering remains a core element of its business model, enabling the company to advance multiple assets in parallel with major industry collaborators. Further information is available at astx.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy